{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:30:23Z","timestamp":1790037023377,"version":"4.0.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T00:00:00Z","timestamp":1596585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T00:00:00Z","timestamp":1596585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Approximately 7\u201310% of Parkinson\u2019s disease (PD) patients carry a GBA (Glucocerebrosidase) mutation (GBA-PD patients), which may influence the disease\u2019s clinical course.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Objectives<\/jats:title>\n<jats:p>This study aimed to explore the patient experience of GBA-PD and identify the most important symptoms and impacts to inform clinical trial measurement strategies.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Twenty PD patients (<jats:italic>n<\/jats:italic>\u00a0=\u200915 GBA-PD; <jats:italic>n<\/jats:italic>\u00a0=\u20095 idiopathic-PD) participated in qualitative interviews which explored concepts spontaneously reported or identified through a literature review. Telephone interviews with five expert clinicians included discussion of a preliminary conceptual model derived from literature. Verbatim transcripts were thematically analysed.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Thirty symptoms reported by patients were categorized as motor, non-motor, and cognitive\/psychiatric. Tremor (<jats:italic>n<\/jats:italic>\u00a0=\u200913), memory loss (n\u2009=\u200913), rigidity\/stiffness (<jats:italic>n<\/jats:italic>\u00a0=\u200911), and speech problems (n\u2009=\u200911) were considered the most important and impactful symptoms by GBA-PD patients, although other symptoms were also relevant to the majority of patients. Key impacts included: sleep disturbances (<jats:italic>n<\/jats:italic>\u00a0=\u200913), handwriting changes (n\u2009=\u200913), reduced social interaction (<jats:italic>n<\/jats:italic>\u00a0=\u200912), dyskinesia (<jats:italic>n<\/jats:italic>\u00a0=\u200910), depressed mood (<jats:italic>n<\/jats:italic>\u00a0=\u20099), and fear of falling (<jats:italic>n<\/jats:italic>\u00a0=\u20098). Key symptoms and impacts reported by GBA-PD patients were consistent with those reported by idiopathic-PD patients. Clinician interview results supported the patient findings, although some clinicians indicated that cognitive\/psychiatric symptoms may present earlier in GBA-PD patients. The concepts emerging from the research informed updates to a conceptual model of GBA-PD patients\u2019 disease experience.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The findings provide in-depth understanding of the patient experience of GBA-PD. The findings confirm that the concepts relevant to assess in GBA-PD are consistent with those relevant to assess in idiopathic-PD; however, greater consideration of cognitive\/psychiatric symptoms may be warranted in GBA-PD populations.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s41687-020-00230-9","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T07:02:39Z","timestamp":1596610959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Patients\u2019 experiences of Parkinson\u2019s disease: a qualitative study in glucocerebrosidase and idiopathic Parkinson\u2019s disease"],"prefix":"10.1186","volume":"4","author":[{"given":"N.","family":"Bonner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.","family":"Peterschmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Z.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Arbuckle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Reaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,5]]},"reference":[{"key":"230_CR1","first-page":"101","volume-title":"The discovery of grounded theory: Strategries for qualitative research","author":"B Glaser","year":"2010","unstructured":"Glaser, B., & Strauss, A. (2010). The constant comparative methods of qualitative analysis. In B. G. Glaser, & A. L. Strauss (Eds.), The discovery of grounded theory: Strategries for qualitative research, (pp. 101\u2013116). New York: Aldine de Gruyter."},{"issue":"3","key":"230_CR2","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/mds.26071","volume":"30","author":"K Brockmann","year":"2015","unstructured":"Brockmann, K., Srulijes, K., Pflederer, S., Hauser, A. K., Schulte, C., Maetzler, W., et al. (2015). GBA-associated Parkinson's disease: Reduced survival and more rapid progression in a prospective longitudinal study. Movement Disorders, 30(3), 407\u2013411.","journal-title":"Movement Disorders"},{"issue":"14","key":"230_CR3","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1002\/mds.22675","volume":"24","author":"C Klein","year":"2009","unstructured":"Klein, C., Schneider, S. A., & Lang, A. E. (2009). Hereditary parkinsonism: Parkinson disease look-alikes\u2014An algorithm for clinicians to \u201cPARK\u201d genes and beyond. Movement disorders: official journal of the Movement Disorder Society, 24(14), 2042\u20132058.","journal-title":"Movement disorders: official journal of the Movement Disorder Society"},{"key":"230_CR4","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1002\/ajh.24057","volume":"90","author":"TM Cox","year":"2015","unstructured":"Cox, T. M., Rosenbloom, B. E., & Barker, R. A. (2015). Gaucher disease and comorbidities: B-cell malignancy and parkinsonism. American Journal of Hematology, 90, S25\u2013S28.","journal-title":"American Journal of Hematology"},{"key":"230_CR5","unstructured":"The Voice of the Patient (2016). A series of reports from the U.S. Food and Drug Administration\u2019s (FDA\u2019s) patient-focused drug development initiative - Parkinson\u2019s disease. Public meeting: September 22, 2015. Silver Spring: Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER)."},{"key":"230_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/jnc.13385","volume":"139","author":"A Migdalska-Richards","year":"2016","unstructured":"Migdalska-Richards, A., & Schapira, A. H. (2016). The relationship between glucocerebrosidase mutations and Parkinson disease. Journal of Neurochemistry, 139, 77\u201390.","journal-title":"Journal of Neurochemistry"},{"issue":"5","key":"230_CR7","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/ana.24777","volume":"80","author":"R Cilia","year":"2016","unstructured":"Cilia, R., Tunesi, S., Marotta, G., Cereda, E., Siri, C., Tesei, S., et al. (2016). Survival and dementia in GBA-associated Parkinson's disease: T he mutation matters. Annals of Neurology, 80(5), 662\u2013673.","journal-title":"Annals of Neurology"},{"key":"230_CR8","doi-asserted-by":"crossref","unstructured":"Soundy, A., Stubbs, B., & Roskell, C. (2014). The experience of Parkinson\u2019s disease: A systematic review and meta-ethnography. Scientific World Journal, 2014. Article ID 613592.","DOI":"10.1155\/2014\/613592"},{"key":"230_CR9","first-page":"56","volume-title":"Research methods for clinical and Health Psychology","author":"H Joffe","year":"2004","unstructured":"Joffe, H., & Yardley, L. (2004). Content and thematic analysis. In D. F. Marks, & L. Yardley (Eds.), Research methods for clinical and Health Psychology, (pp. 56\u201368). London: Sage Publications."},{"issue":"9","key":"230_CR10","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","volume":"15","author":"HF Hsieh","year":"2005","unstructured":"Hsieh, H. F., & Shannon, S. E. (2005). Three approaches to qualitative content analysis. Quaity Health Research, 15(9), 1277\u20131288.","journal-title":"Quaity Health Research"},{"issue":"1","key":"230_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1525822X05279903","volume":"18","author":"G Guest","year":"2006","unstructured":"Guest, G., Bunce, A., & Johnson, L. (2006). How many interviews are enough? An experiment with data saturation and variability. Field Methods, 18(1), 59\u201382.","journal-title":"Field Methods"},{"issue":"10","key":"230_CR12","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1080\/08870440903194015","volume":"25","author":"JJ Francis","year":"2010","unstructured":"Francis, J. J., Johnston, M., Robertson, C., Glidewell, L., Entwistle, V., Eccles, M. P., et al. (2010). What is an adequate sample size? Operationalising data saturation for theory-based interview studies. Psychology & Health, 25(10), 1229\u20131245.","journal-title":"Psychology & Health"},{"key":"230_CR13","unstructured":"Foundation Ps (2019). Speech & Swallowing Problems Parkinson's foundation. Parkinson's Foundation Available from: https:\/\/www.parkinson.org\/Understanding-Parkinsons\/Symptoms\/Non-Movement-Symptoms\/Speech-and-Swallowing-Problems."},{"issue":"9","key":"230_CR14","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1212\/01.wnl.0000176987.47875.28","volume":"65","author":"J Aharon-Peretz","year":"2005","unstructured":"Aharon-Peretz, J., Badarny, S., Rosenbaum, H., & Gershoni-Baruch, R. (2005). Mutations in the glucocerebrosidase gene and Parkinson disease: Phenotype\u2013genotype correlation. Neurology., 65(9), 1460\u20131461.","journal-title":"Neurology."},{"issue":"3","key":"230_CR15","first-page":"725","volume":"35","author":"C Wang","year":"2014","unstructured":"Wang, C., Cai, Y., Gu, Z., Ma, J., Zheng, Z., Tang, B.-S., et al. (2014). Clinical profiles of Parkinson's disease associated with common leucine-rich repeat kinase 2 and glucocerebrosidase genetic variants in Chinese individuals. Neurobiology of Aging, 35(3), 725 e1-. e6.","journal-title":"Neurobiology of Aging"},{"key":"230_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jns.2016.08.059","volume":"370","author":"M Swan","year":"2016","unstructured":"Swan, M., Doan, N., Ortega, R. A., Barrett, M., Nichols, W., Ozelius, L., et al. (2016). Neuropsychiatric characteristics of GBA-associated Parkinson disease. Journal of the Neurological Sciences, 370, 63\u201369.","journal-title":"Journal of the Neurological Sciences"},{"issue":"9","key":"230_CR17","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1002\/acn3.228","volume":"2","author":"Z Gan-Or","year":"2015","unstructured":"Gan-Or, Z., Mirelman, A., Postuma, R. B., Arnulf, I., Bar-Shira, A., Dauvilliers, Y., et al. (2015). GBA mutations are associated with rapid eye movement sleep behavior disorder. Annals of Clinical Translational Neurology, 2(9), 941\u2013945.","journal-title":"Annals of Clinical Translational Neurology"},{"key":"230_CR18","doi-asserted-by":"crossref","unstructured":"Ben-Joseph, A., Marshall, C. R., Lees, A. J., & Noyce, A. J. (2019Preprint). Ethnic variation in the manifestation of Parkinson\u2019s disease: A narrative review. Journal of Parkinson's Disease, 10(1), 1\u201315.","DOI":"10.3233\/JPD-191763"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-020-00230-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-020-00230-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-020-00230-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T23:03:36Z","timestamp":1628118216000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-020-00230-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,5]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["230"],"URL":"https:\/\/doi.org\/10.1186\/s41687-020-00230-9","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,5]]},"assertion":[{"value":"30 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved and overseen by Copernicus Group Independent Review Board (IRB), a centralized review board in the US (reference: ADE1\u201317-542). Patients and clinicians provided written informed consent prior to any study activities including the collection of any of their data.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The study was funded by Sanofi, who commissioned Adelphi Values, a health outcomes agency by whom N Bonner, L Morgan, B Mason and R Arbuckle are employed to conduct this research. S Bozzi, J Peterschmitt are employed by Sanofi. M Reaney and TZ Fischer were employed by Sanofi at the time this research was conducted. No other conflicts are reported.The authors declare that they have other no competing interests in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}